Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 7/20 | 0.37 |
| ▸ | PARP1 | P09874 | 7/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 7/20 | 0.37 |
| ▸ | ERN1 | O75460 | 2/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.34 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | TYR | P14679 | 2/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.33 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12024979 | 0.85 | ALOX5AP (0.38) | TNKSPARP1TNKS2ERN1 | |
| SCHEMBL16043928 | 0.83 | CYP1A1 (0.36) | ERN1CYP1A1CYP1B1PDE2ATYR | |
| SCHEMBL3503786 | 0.81 | APP (0.40) | ERN1CYP1A1CYP1B1AKR1C3AKR1C2 | |
| SCHEMBL14010989 | 0.80 | CYP1A1 (0.37) | TNKSPARP1TNKS2CYP1A1CYP1B1 | |
| SCHEMBL12732541 | 0.80 | CYP1A1 (0.37) | TNKSPARP1TNKS2CYP1A1CYP1B1 | |
| SCHEMBL16741144 | 0.79 | ALDH1A1 (0.36) | ERN1CYP1A1CYP1B1AKR1C3AKR1C2 | |
| SCHEMBL153434 | 0.79 | CYP1A1 (0.44) | CYP1A1CYP1B1PDE2A | |
| SCHEMBL19433353 | 0.77 | PTGS1 (0.31) | ERN1CYP1A1CYP1B1 | |
| Ammonia Solution, Strong SCHEMBL28850606 | 0.77 | CYP1A1 (0.43) | CYP1A1CYP1B1PDE2A | |
| Hydrochloric Acid SCHEMBL27743327 | 0.77 | IDO1 (0.43) | CYP1A1CYP1B1PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189839-B2 | Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase | ACTELION PHARMACEUTICALS LTD (CH) | 2019-01-29 | — | — | US | disclosed |
| US-20180155344-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-06-07 | — | — | US | disclosed |
| EP-3292127-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | Actelion Pharmaceuticals Ltd (CH) | 2018-03-14 | — | — | EP | disclosed |
| EP-3071578-B1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-01-10 | — | — | EP | disclosed |
| US-9765092-B2 | Tricyclic piperidine compounds | ACTELION PHARMACEUTICALS LTD (CH) | 2017-09-19 | — | — | US | disclosed |
| EP-3071567-B1 | TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE | ACTELION PHARMACEUTICALS LTD (CH) | 2017-09-06 | — | — | EP | disclosed |
| WO-2016177690-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-11-10 | — | — | WO | disclosed |
| US-20160289232-A1 | TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE | ACTELION PHARMACEUTICALS LTD (CH) | 2016-10-06 | — | — | US | disclosed |
| EP-3071578-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | Actelion Pharmaceuticals Ltd (CH) | 2016-09-28 | — | — | EP | disclosed |
| EP-3071567-A1 | TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE | Actelion Pharmaceuticals Ltd (CH) | 2016-09-28 | — | — | EP | disclosed |
| EP-2278969-B1 | Inhibitors of Janus kinases | MERCK SHARP & DOHME (US) | 2013-02-13 | — | — | EP | disclosed |
| EP-2278969-B1 | Inhibitors of Janus kinases | MERCK SHARP & DOHME (US) | 2013-02-13 | — | — | EP | disclosed |
| US-8278335-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278335-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278335-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20110166129-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-07-07 | — | — | US | disclosed |
| US-20110166129-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-07-07 | — | — | US | disclosed |
| US-20110166129-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-07-07 | — | — | US | disclosed |
| EP-2278969-A2 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2011-02-02 | — | — | EP | disclosed |
| WO-2010011375-A2 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189839-B2 | Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase | TPH1, TPH2, MAOB | TNKS 1348/4885PARP1 1875/4885TNKS2 1978/4885 |
| US-20180155344-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | TPH1, TPH2, HTR1B | TNKS 481/4885PARP1 559/4885TNKS2 958/4885 |
| US-20110166129-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | TNKS 718/4885PARP1 1274/4885TNKS2 844/4885 |
| US-20160289232-A1 | TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE | TPH1, TPH2, MAOB | TNKS 1348/4885PARP1 1875/4885TNKS2 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.